Preference of treatment characteristics among people with haemophilia or their caregivers, and physicians in the Japanese healthcare environment
Haemophilia · 2024
DOI: 10.1111/hae.15028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2024. Verfasst von Teruhisa Fujii und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transfusion Medicine, Hemophilia Treatment Center, Hiroshima University Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Caregivers, Physicians. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Pharma Ltd. (Tokyo, Japan), Novo Nordisk Pharma.
Abstract (Originalsprache)
Introduction
Studies of treatment preferences in haemophilia have been conducted in many countries. This study is the first to examine treatment characteristic preferences among people with haemophilia (PWH) and their caregivers, and physicians in Japan.
Aim
To examine current treatment preferences of PWH and their caregivers, plus those of physicians at haemophilia treatment centres (HTCs) and non‐HTCs for different treatment characteristics in Japan.
Methods
Physicians listed on a survey panel were invited to participate in the survey and to refer PWH and caregivers to participate in the survey. Web‐based surveys were conducted to examine physician and PWH/caregiver background, prophylaxis background, prophylaxis goals, understanding of haemophilia treatment products, important information sources, preferences while choosing prophylaxis products, understanding of the patient's condition, and potential product switching. A discrete choice experiment exercise was included in the survey.
Results
A total of 107 physicians and 44 PWH/caregivers participated in the study. Key treatment goals of physicians included optimisation of haemophilia management. PWH/caregivers were focused on quality of life and reduced treatment burden. Consistent differences in haemophilia treatment strategies at HTCs and non‐HTCs were observed for prescribed treatments, preferences in choosing prophylaxis products, understanding of patients’ condition, and reasons for potential product switch.
Conclusion
Our study utilises real‐world survey data and presents preferences for haemophilia treatment characteristics among physicians, PWH and their caregivers in Japan, which could encourage improvements in individualised treatment and disease management. Alignment between treatment approaches at HTCs and non‐HTCs could facilitate improvements in the quality of care for PWH across Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Transfusion Medicine, Hemophilia Treatment Center, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University Hospital, Fukuoka, Japan.
- Medical Affairs Department, Novo Nordisk Pharma Ltd., Tokyo, Japan.
ORCID-Profile: Teruhisa Fujii
Förderung
- Novo Nordisk Pharma Ltd. (Tokyo, Japan)
- Novo Nordisk Pharma
Zitieren
APA
Fujii, T., Ishimura, M., Takao, S., & Deguchi, A. (2024). Preference of treatment characteristics among people with haemophilia or their caregivers, and physicians in the Japanese healthcare environment. Haemophilia. https://doi.org/10.1111/hae.15028
Vancouver
Fujii T, Ishimura M, Takao S, Deguchi A. Preference of treatment characteristics among people with haemophilia or their caregivers, and physicians in the Japanese healthcare environment. Haemophilia. 2024. doi:10.1111/hae.15028
BibTeX
@article{Fujii2024,
author = {Fujii, Teruhisa and Ishimura, Masataka and Takao, Satomi and Deguchi, Ayumi},
title = {Preference of treatment characteristics among people with haemophilia or their caregivers, and physicians in the Japanese healthcare environment},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.15028}
}
EUVIMED